» Articles » PMID: 8281615

Vascular Permeability Factor (VPF, VEGF) in Tumor Biology

Overview
Specialty Oncology
Date 1993 Sep 1
PMID 8281615
Citations 212
Authors
Affiliations
Soon will be listed here.
Abstract

Vascular permeability factor (VPF), also known as vascular endothelial growth factor (VEGF), is a multifunctional cytokine expressed and secreted at high levels by many tumor cells of animal and human origin. As secreted by tumor cells, VPF/VEGF is a 34-42 kDa heparin-binding, dimeric, disulfide-bonded glycoprotein that acts directly on endothelial cells (EC) by way of specific receptors to activate phospholipase C and induce [Ca2+]i transients. Two high affinity VPF/VEGF receptors, both tyrosine kinases, have thus far been described. VPF/VEGF is likely to have a number of important roles in tumor biology related, but not limited to, the process of tumor angiogenesis. As a potent permeability factor, VPF/VEGF promotes extravasation of plasma fibrinogen, leading to fibrin deposition which alters the tumor extracellular matrix. This matrix promotes the ingrowth of macrophages, fibroblasts, and endothelial cells. Moreover, VPF/VEGF is a selective endothelial cell (EC) growth factor in vitro, and it presumably stimulates EC proliferation in vivo. Furthermore, VPF/VEGF has been found in animal and human tumor effusions by immunoassay and by functional assays and very likely accounts for the induction of malignant ascites. In addition to its role in tumors, VPF/VEGF has recently been found to have a role in wound healing and its expression by activated macrophages suggests that it probably also participates in certain types of chronic inflammation. VPF/VEGF is expressed in normal development and in certain normal adult organs, notably kidney, heart, adrenal gland and lung. Its functions in normal adult tissues are under investigation.

Citing Articles

ENDOGLIN (CD105): A marker of tumour vasculature for assessment of malignant potential of oral submucous fibrosis.

Shetty S, Pereira T, Tamgadge S, Kale S, Kamat P, Kumar S J Oral Maxillofac Pathol. 2025; 28(4):589-595.

PMID: 39949694 PMC: 11819617. DOI: 10.4103/jomfp.jomfp_67_24.


Molecular Insights on Signaling Cascades in Breast Cancer: A Comprehensive Review.

Panda V, Mishra B, Mahapatra S, Swain B, Malhotra D, Saha S Cancers (Basel). 2025; 17(2).

PMID: 39858015 PMC: 11763662. DOI: 10.3390/cancers17020234.


Research progress and treatment status of malignant ascites.

He J, Zhang H Front Oncol. 2024; 14:1390426.

PMID: 39737405 PMC: 11682990. DOI: 10.3389/fonc.2024.1390426.


Perioperative Treatment in Gastric Cancer: A Fast-Changing Field.

Costa M, Fernandes C, Magalhaes H Cancers (Basel). 2024; 16(23).

PMID: 39682222 PMC: 11640278. DOI: 10.3390/cancers16234036.


TNFAIP2 promotes HIF1α transcription and breast cancer angiogenesis by activating the Rac1-ERK-AP1 signaling axis.

Ren W, Liang H, Sun J, Cheng Z, Liu W, Wu Y Cell Death Dis. 2024; 15(11):821.

PMID: 39532855 PMC: 11557851. DOI: 10.1038/s41419-024-07223-2.


References
1.
Dvorak H, Nagy J, Dvorak J, Dvorak A . Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol. 1988; 133(1):95-109. PMC: 1880651. View

2.
Underwood J, Carr I . The ultrastructure and permeability characteristics of the blood vessels of a transplantable rat sarcoma. J Pathol. 1972; 107(3):157-66. DOI: 10.1002/path.1711070303. View

3.
Costantini V, Zacharski L, Memoli V, Kisiel W, Kudryk B, Rousseau S . Fibrinogen deposition without thrombin generation in primary human breast cancer tissue. Cancer Res. 1991; 51(1):349-53. View

4.
Nagy J, Herzberg K, Masse E, Zientara G, Dvorak H . Exchange of macromolecules between plasma and peritoneal cavity in ascites tumor-bearing, normal, and serotonin-injected mice. Cancer Res. 1989; 49(19):5448-58. View

5.
Lanir N, Ciano P, Van de Water L, McDonagh J, Dvorak A, Dvorak H . Macrophage migration in fibrin gel matrices. II. Effects of clotting factor XIII, fibronectin, and glycosaminoglycan content on cell migration. J Immunol. 1988; 140(7):2340-9. View